Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Methotrexate
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Metoject PEN 30mg/0.6ml inj pre-filled pens
1001030U0BEAVCA
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 117 |
|
Methotrexate 12.5mg/0.5ml inj pre-filled disposable devices
0801030P0AAFPFP
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 108 |
|
Methofill 25mg/0.5ml inj pre-filled syringes
1001030U0BGARBI
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 99 |
|
Methofill 12.5mg/0.25ml inj pre-filled injector
1001030U0BGACCD
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 98 |
|
Zlatal 15mg/0.6ml solution for injection pre-filled syringes
0801030P0BEAGFK
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 93 |
|
Methofill 17.5mg/0.35ml inj pre-filled injector
1001030U0BGAEBV
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 91 |
|
Methofill 15mg/0.3ml inj pre-filled syringes
1001030U0BGAMBG
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 89 |
|
Methotrexate 22.5mg/0.9ml inj pre-filled disposable devices
0801030P0AAFTFT
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 83 |
|
Methotrexate 7.5mg/0.3ml inj pre-filled disposable devices
0801030P0AAFMFM
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 77 |
|
Methotrexate 10mg/0.4ml inj pre-filled syringes
0801030P0AAFHFH
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 75 |
|
Methofill 10mg/0.2ml inj pre-filled syringes
1001030U0BGALBF
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 72 |
|
Methofill 22.5mg/0.45ml inj pre-filled injector
1001030U0BGAGBX
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 66 |
|
Methotrexate 22.5mg/0.9ml inj pre-filled syringes
0801030P0AAFFFF
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 52 |
|
Methofill 7.5mg/0.15ml inj pre-filled injector
1001030U0BGAABY
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 51 |
|
Methotrexate 7.5mg/0.3ml inj pre-filled syringes
0801030P0AAFIFI
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 51 |
|
Methotrexate 17.5mg/0.7ml inj pre-filled syringes
0801030P0AAFLFL
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 50 |
|
Zlatal 25mg/1ml solution for injection pre-filled syringes
0801030P0BEACFG
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 48 |
|
Maxtrex 10mg tablets
1001030U0BDABAC
|
Maxtrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 39 |
|
Metoject PEN 27.5mg/0.55ml inj pre-filled pens
1001030U0BEAUBZ
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 39 |
|
Methotrexate 12.5mg/0.5ml inj pre-filled syringes
0801030P0AAFJFJ
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 36 |
|
Zlatal 10mg/0.4ml solution for injection pre-filled syringes
0801030P0BEADFH
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 34 |
|
Zlatal 7.5mg/0.3ml inj pre-filled syringes
0801030P0BEAEFI
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 28 |
|
Methofill 17.5mg/0.35ml inj pre-filled syringes
1001030U0BGANBL
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 26 |
|
Methotrexate 30mg/0.6ml inj pre-filled disposable devices
1001030U0AACACA
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 23 |
|
Zlatal 17.5mg/0.7ml inj pre-filled syringes
0801030P0BEAHFL
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 23 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.